Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

The future of San Francisco’s Mexican Museum is in jeopardy after the beleaguered organization missed a key fundraising deadline for the construction of its long-gestating downtown location. The ...

The tender evaluation committee of the State Department for Housing and Urban Development had recommended Keddy Enterprises ...